摘要
Our comprehensive review focuses on the treatment of hepatitis C virus in the context of hepatocellular carcinoma and vice versa,highlighting the ongoing complexity of this clinical scenario.There remain multiple unanswered questions when considering the management of these complex patients and,with a rapidly-changing treatment landscape for both chronic hepatitis C and hepatocellular carcinoma,these questions are only going to grow.Treatment timing,interactions and the impact of one disease condition on the other are vitally important,though guidance generally remains non-specific,suggesting that we make these decisions on a case-by-case basis.We focus on the current evidence for managing these cases,depending on disease stage and treatment type.
基金
CMV is a recipient of a grant from Gilead,Canada.
